What a Patient Registry Can Do for Gynecologic Cancer Research

By Allison Ramiller, OCRA Senior Director of the Living Lab Registry

Gynecologic cancers have long been underrepresented in cancer research relative to their burden.

Despite decades of research, important questions remain unanswered in ovarian, uterine, and other gynecologic cancers: why does the same treatment work for one patient but not another? Why do outcomes differ so much depending on a patient's race or income? What happens to people in the years after treatment — how does their health, quality of life, and risk of other conditions evolve over time? A patient registry is a powerful tool to answer critical questions like these.

What is a patient registry?
A patient registry brings together health information from people who share something in common, such as a specific diagnosis or related disease conditions. It typically includes clinical information alongside information that patients share about their own lives and experiences. When thousands of people contribute their data, patterns become visible that no single doctor, hospital, or study could detect on their own.

Registries that follow participants over time and collect data at multiple points are especially valuable. They allow researchers to track how disease and quality of life evolve in ways that a single snapshot in time simply cannot reveal.

Registries in action: examples from other diseases
Before a dedicated registry existed for Rett Syndrome, a rare neurological disease, the condition was severely understudied. After one was established, the number of published studies increased, new researchers entered the field, and clinical trials launched.[1] That accumulated knowledge and effort contributed to FDA approval for the first-ever Rett Syndrome treatment in 2023.[2]

The Cystic Fibrosis Foundation built its patient registry in the 1960s and revealed something striking: patients at some treatment centers were doing significantly better than patients at others.[3] That finding drove hospitals to examine and improve their practices and helped researchers develop the targeted therapies that have dramatically extended life expectancy for people with CF.[4]

In type 1 diabetes, the T1D Exchange Clinic Registry brought together more than 26,000 patients across 67 clinical sites. The data generated directly shaped treatment guidelines and exposed gaps in care; for example, continuous glucose monitoring was being underused in the patients most likely to benefit from it.[5]

The potential of a patient registry for gynecologic cancer
Ovarian, uterine, and other gynecologic cancers are not single, uniform diseases. They encompass multiple subtypes with different biology, different responses to treatment, and different long-term trajectories. We are still learning what distinguishes them. The need for large, diverse, longitudinal data is clear when you layer on the reality that outcomes vary significantly by race, income, and access to care.

That is exactly what a well-designed registry can provide. By pooling information from a diverse set of individuals across the country, it generates the kind of sample size needed to study rare subtypes, better understand risk and outcomes, and detect patterns that would be invisible in any single institution's data. Additionally, patient surveys can capture what medical records alone never will — real-world data that describes the patient experience and what life looks like during and after treatment. Using the infrastructure a registry provides, researchers can generate and test new hypotheses, validate findings, and recruit for future studies without starting from scratch each time.

For too long, gynecologic cancers have not attracted research investment commensurate with their impact on patients’ lives. A registry purpose-built for this population is a step toward changing that.

Learn more about OCRA’s ovarian and uterine patient registry, the Living Lab.

Sources

[1] https://www.rettsyndrome.org/rett-syndrome-registry/

[2] https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-rett-syndrome

[3] https://datacatalog.med.nyu.edu/dataset/10129

[4] Cystic Fibrosis Foundation. Patient Registry Annual Data Report. cff.org

[5] Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA; T1D Exchange Clinic Network. The T1D Exchange clinic registry. J Clin Endocrinol Metab. 2012 Dec;97(12):4383-9. doi: 10.1210/jc.2012-1561. Epub 2012 Sep 20. PMID: 22996145.